Abiomed Is Expensive - Cramer's Lightning Round (7/19/16)

|
Includes: ABMD, BMY, EW, HAR, JNJ, JUNO
by: SA Editor Mohit Manghnani

Summary

Harman International needs good quarters to restore faith.

Juno Therapeutics is getting difficult.

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, July 19.

Bearish Calls

Abiomed (NASDAQ:ABMD): It's slightly expensive to get a takeover bid, just like Edwards Lifesciences (NYSE:EW), which is too big to be acquired.

Harman International (NYSE:HAR): It has been hurt by the strong dollar and is cheap with $5.5B market cap. However, its quarters have been rocky and CEO Dinesh Paliwal needs to deliver.

Juno Therapeutics (NASDAQ:JUNO): "We don't do the clinical stages anymore. Remember they have gotten way too difficult." Johnson & Johnson (NYSE:JNJ) and Bristol-Myers (NYSE:BMY) are better picks.

[Editor's note: There were no Bullish Calls on Tuesday's show.]

:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Jim Cramer's Action Alerts PLUS: Check out Cramer's multi-million dollar charitable trust portfolio and uncover the stocks he thinks could be HUGE winners. Start your FREE 14-day trial now!

Get Cramer's Picks by email - it's free and takes only a few seconds to sign up.